Suzanne Topalian
Johns Hopkins University
H-index: 106
North America-United States
Top articles of Suzanne Topalian
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial | The Lancet Oncology | Ana Oaknin Kathleen Moore Tim Meyer José López-Picazo González Lot A Devriese | 2024/4/9 |
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade | Journal of translational medicine | Shuming Chen Tracee L McMiller Abha Soni Farah Succaria John-William Sidhom | 2024/3/5 |
Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma | Cell Reports Medicine | Thomas Pulliam Saumya Jani Lichen Jing Heeju Ryu Ana Jojic | 2024/2/20 |
T antigen-specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma | The Journal of Clinical Investigation | Ulla Kring Hansen Candice D Church Ana Micaela Carnaz Simões Marcus Svensson Frej Amalie Kai Bentzen | 2024/1/30 |
Nivolumab+ Tacrolimus+ Prednisone±Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers | Journal of Clinical Oncology | Kara M Schenk Julie Stein Deutsch Sunandana Chandra Diwakar Davar Zeynep Eroglu | 2024/1/22 |
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma | Cell Reports Medicine | Julie Stein Deutsch Evan J Lipson Ludmila Danilova Suzanne L Topalian Jaroslaw Jedrych | 2023/2/21 |
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy | Suzanne L Topalian Patrick M Forde Leisha A Emens Mark Yarchoan Kellie N Smith | 2023/9/11 | |
Five-year clinical outcomes after neoadjuvant nivolumab in resectable non–small cell lung cancer | Clinical Cancer Research | Samuel Rosner Joshua E Reuss Marianna Zahurak Jiajia Zhang Zhen Zeng | 2023/2/16 |
Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO)±ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma … | Shailender Bhatia Suzanne Louise Topalian William Howard Sharfman Tim Meyer Christopher D Lao | 2023/6/1 | |
Characterizing tumor stromal evolution after neoadjuvant anti-PD-1 therapy in Merkel cell carcinoma | Cancer Research | Joel C Sunshine Tracee L McMiller Alyza Skaist Yan Zhang Alan Berger | 2023/4/4 |
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Journal of Clinical Oncology | Suzanne L Topalian Mario Sznol David F McDermott Harriet M Kluger Richard D Carvajal | 2023/2/10 |
Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates | Journal of Clinical Oncology | Julie R Brahmer Charles G Drake Ira Wollner John D Powderly Joel Picus | 2023/2/1 |
The COX-2/PGE2 pathway as a mediator of resistance to anti-PD-1 therapy | Cancer Research | Shuming Chen Seoho Lee Tracee L McMiller Isaac Morales Preethi Sankaran | 2023/4/4 |
Data from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer | Samuel Rosner Joshua E Reuss Marianna Zahurak Jiajia Zhang Zhen Zeng | 2023/4/1 | |
Checkpoint blockade and microsatellite instability | 2023/11/16 | ||
50 Merkel cell polyomavirus-specific CD8 T cells in blood, but not in tumors, correlate with immunotherapy response in merkel cell carcinoma | Thomas Pulliam Saumya Jani Lichen Jing Jiajia Zhang Rima Kulikauskas | 2022/11/1 | |
711 Interim results of a phase 2 study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L) 1 inhibition | J Immunother | Katherine Bever Hao Wang Jennifer Durham Colleen Apostol Nilofer Azad | 2022 |
820P Nivolumab (NIVO)+/-relatlimab (RELA) or ipilimumab (IPI) for patients (pts) with advanced treatment-naïve or-refractory basal cell carcinoma (BCC) | Annals of Oncology | KM Schenk JS Deutsch MD Schollenberger WH Sharfman PN Brothers | 2022/9/1 |
520MO Safety and efficacy of nivolumab (NIVO)±ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358 | Annals of Oncology | A Oaknin KN Moore T Meyer JL González L Devriese | 2022/9/1 |
LB1029 Correlation of merkel virus-specific CD8 T cells with response to immunotherapy in merkel cell carcinoma | Journal of Investigative Dermatology | T Pulliam S Jani L Jing J Zhang R Kulikauskas | 2022/8/1 |
